According to a release issued by Orchid Chemicals and Pharmaceuticals to the BSE today, the alliance will cover the US, Canadian, European and Australian markets.
"Sales out of this alliance will happen in a year, and the impact could be seen in turnover and profitability in the beginning of 2007. The products will mature during 2007-09, " M D Raghavendra Rao, managing director of Orchid, said.
Mayne will fund Orchid to develop the products with the execution of agreement, and the profits would be shared between the partners, the release added.
